---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-000584"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:40:14.607978+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# VYNE Therapeutics appoints Christine Borowski, Ph.D., to board of directors effective Jan 1, 2024

## Summary
- Appointed Dr. Christine Borowski as Class II director, effective Jan 1, 2024, for term until 2026 annual meeting.
- Dr. Borowski is Vice President at Access Bio and was appointed per prior agreement from Nov 2023 private placement.
- Received option to purchase 40,000 shares at $2.33/share, vesting annually over 3 years.
- Will receive standard annual cash retainer of $40,000, payable quarterly, plus annual option awards.

## SEC filing metadata
- accession: 0001104659-24-000584
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465924000584/0001104659-24-000584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465924000584/tm2333851d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-000584
- JSON: https://secwatch.observer/filing/0001104659-24-000584.json
- Plain text: https://secwatch.observer/filing/0001104659-24-000584.txt

## Key facts
- Executive change
  Christine Borowski was appointed as Director at VYNE Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: On December 29, 2023, the Board appointed Dr. Christine Borowski to serve as a Class II director of the Company, effective as of January 1, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465924000584/0001104659-24-000584-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.